FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Amgen Gets Superiority Data Approved for Kyprolis Label

FDA approves an Amgen supplemental NDA to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the prescribing information f...

Medical Devices

Metrics Needed to Evaluate Least Burdensome: GAO

FDA commissioner Scott Gottlieb says he agrees with the Government Accountability Office that the agency needs to develop and use performance metrics ...

Human Drugs

Medical Countermeasure Priority Voucher Guidance

FDA issues a draft guidance responding to questions raised about the legal requirement to offer a priority review voucher to sponsors of certain medic...

Federal Register

FDA Withdraws 22 ANDAs No Longer Marketed

Federal Register notice: FDA withdraws approval of 22 ANDAs from multiple applicants.

Federal Register

Proposed Rule on CDRH Supervisory Review of Certain Actions

Federal Register proposed rule: FDA proposes to implement regulations regarding internal agency supervisory review of certain decisions related to dev...

Federal Register

OMB Approval Sought for Genomic Test Info Collection

Federal Register notice: FDA submits for OMB clearance a new information collection entitled Use of Public Human Genetic Variant Databases To Support ...

Human Drugs

Baxter Expands Nexterone Recall Due to Particulate Matter

Baxter International expands its recall of one lot of Nexterone (amiodarone HCl) 150 mg/100 mL premixed injection to include a second lot due to the p...

FDA Says Many Risks Associated with Imprimis Compounded Drugs

FDA warns Imprimis Pharmaceuticals about many false or misleading claims in promotional materials for its compounded drugs.

Medical Devices

CDRH Sets 3 Strategic Priorities for 2018-2020

CDRH takes credit for steps to meet its 2012-2017 strategic priorities and sets new priorities for 2018-2020.

Human Drugs

Gottlieb Unveils New Transparency Initiatives

FDA launches a new pilot to offer more transparency with drug approval decisions, among other initiatives to help understand the agencys regulatory ac...